Board of Directors

Graham was appointed to the Board on 13 July 2026. Over more than four decades he has held leadership, board and governance roles across the advanced engineering, manufacturing and technology sectors. He previously served as Chairman of Westland Helicopters and held a number of senior executive positions within the AgustaWestland Group. He also served on the Board of parent company Finmeccanica UK and has held a range of non-executive and advisory positions across industry. In addition, Graham has served on several UK Government ministerial committees. In 2024 he was appointed a Commander of the Order of the British Empire (CBE) for services to the aerospace industry and holds Freedom to the City of London.

Gino was appointed Chief Executive Officer on 6 August 2024 and a Director and Chief Scientific Officer on 11 September 2023. He has considerable experience in the development of molecular diagnostic technologies and instrumentation, and has been the R&D Director at genedrive since 2015 and its predecessor Epistem since 2011. Prior to that Gino served as Associate Director for clinical translational genomics at Wyeth and Pfizer. Gino has been a key driver in the development of the genedrive® system and positioning of point of care pharmacogenetic testing in emergency healthcare.

Russ was appointed Chief Financial Officer on 7 April 2022. He is an experienced finance executive and business leader with a 25-year international career spanning life sciences, diagnostics, technology and industrials. Prior to joining genedrive, he spent 10 years as Finance Director of AIM-listed Driver Group plc, supporting its scale-up, international expansion and strategic turnaround. He has held senior finance positions across a diverse range of businesses, from technology start-ups through to his role as CFO of an exceptionally high-growth private company that scaled to more than £100 million in annual revenues. Russ is a qualified accountant and treasury professional.

Chris was appointed to Board on 22 August 2018. He is currently CEO of Abingdon Health plc, a position he has held since July 2015. Chris co-founded Abingdon in 2008 and was a non-executive of the company prior to his appointment as CEO. Chris has over 20 years experience of working in listed environments and prior to working at Abingdon, was CFO at Immunodiagnostic Systems Holdings PLC and Cozart plc. Chris is a Chartered Accountant and has a degree in economics from Cambridge University.

David was appointed to Board on 26 May 2026. He is a UK-based serial entrepreneur, private investor and strategic backer of growth-stage companies. David is the founder and director of a number of private businesses, reflecting a broad background in entrepreneurship and private investment across multiple sectors and is the largest shareholder in the Company.